

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

BPC-157 is being investigated for soft-tissue, gastrointestinal, vascular, and nerve repair, with benefits demonstrated in specific animal models and preliminary symptom findings in small human studies. [3–5,16–19,22,23] It is an experimental synthetic 15-amino-acid peptide, described as a fragment of a protein isolated from human gastric juice. [2,4] Experimental effects include tendon-cell migration, vascular signaling, and tissue repair. [6,8,9] These findings make corresponding human benefits plausible, but do not establish the effectiveness of the proposed SC schedules. [7,25,29]

 Short-term tolerability has been reported under limited human study conditions. Safety of long-term exposure has not been established. [1,23,24]

★ ★ Repair effects demonstrated in several animal models; corresponding human clinical benefits remain plausible. [3–8,25]

C Pro-angiogenic: Particular caution is warranted with active or recently treated cancer. Experimental angiogenic signaling creates a plausible concern about tumor vascularization; clinical tumor promotion has not been demonstrated. [8,21]

Disclaimer: These notes are not authoritative and should not be interpreted as definitive scientific guidance. They are summaries, compilations and plausible extrapolations drawn from the most relevant research I was able to locate, and may omit nuances, conflicting data, or emerging evidence. The material reflects an attempt to organize and understand complex topics, not to provide clinical recommendations or expert interpretation.

Long-term safety cannot be assigned one reassuring rating: liver and clotting signals require resolution, while negative genotoxicity tests provide a narrower, favorable finding. [1,11]

Soft-tissue repair is supported by positive rodent and cell studies, but replication is not uniformly positive. [3–6,25] Conserved repair pathways support plausible human benefit. [7–10,25]

Dosing Patterns

From key animal studies

Animal Regimen	Human Equivalent Dose (150 lbs) [26] ¹
rat, IP, ligament repair [4]	110 mcg daily; up to 90 days
rat, oral, ligament repair [4]	
rat, IP, tendon repair [25]	110 mcg daily for 30 days
rat, IP, incisional pain [15]	110, 220, or 440 mcg once, 60 minutes before incision

¹ FDA body-surface-area scaling guidance.

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

The following speculative, experimental doses and patterns are frequently discussed. [1,29]

For specific injury repair

- **100–500 mcg SC once or twice daily for 2–8 weeks**

Any additional benefit from injecting near an injury is speculative; the intra-articular knee study does not test this SC approach. [22]

For chronic injuries and age-related stiffness

- **100–500 mcg SC daily to once weekly**

Potential for Diminishing Benefit

BPC-157 has no established primary binding target and influences several downstream pathways. [1,6,8,9] Classical receptor desensitization has not been demonstrated. Adaptation with continuous exposure is a hypothesis, rather than an established reason to cycle treatment.

Community cycling patterns

Continuous daily dosing, weekly maintenance, and periodic breaks remain speculative schedules. [1,29]

Benefits

The experimental evidence supports tissue-protective and repair mechanisms, while preliminary human reports suggest possible symptom benefit. [3–9,22,23]

- **Tendon and ligament repair:** Rat Achilles-tendon and medial-collateral-ligament experiments reported improved tissue organization, function, and biomechanical repair. [3,4] Tendon-cell migration and explant outgrowth were demonstrated separately. [6] Another rat study found biomarker BPC-157 improvements without statistically significant differences in failure load or total Bonar and Movin scores; its small groups limit precision. [25]
- **Muscle repair:** Rat crush-injury experiments reported improved healing and function, including under corticosteroid exposure. [5] A quadriceps-transection study also found improved regeneration and biomechanical and functional recovery. [27] Corresponding human muscle-repair benefits are plausible. [29]
- **Intra-articular knee-pain relief:** A very small retrospective series reported substantial improvement, reported 6–12 months after injection, but without control groups or standardized functional assessment. [22]
- **Gastrointestinal protection and repair:** Rodent studies reported reduced NSAID-associated lesions, improved fistula closure, and stronger ileoileal anastomoses. [12,13,28] These findings make human benefit plausible. Another randomized ulcerative-colitis enema study did not establish a clear between-group benefit. [1]

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

- **Interstitial-cystitis symptoms:** A very small uncontrolled retrospective study reported 80% improvement in two at six weeks after one 10 mg bladder-wall injection procedure. These subjective results apply to local bladder-wall administration, not ordinary SC dosing or simple bladder instillation. [23]
- **Microvascular repair:** BPC-157 increased vessel formation in experimental assays and improved blood-flow recovery in rat hind-limb ischemia. [8] Endothelial nitric-oxide signaling provides a plausible mechanism for vascular effects. [9]
- **Acute neurologic injury:** Mouse traumatic-brain-injury and rat spinal-cord and hippocampal ischemia/reperfusion experiments reported less injury and improved functional outcomes. [17–19] The spinal experiment chiefly assessed tail function after sacrocaudal injury; the ischemia study used a local application near the operated carotid arteries. [18,19]
- **Inflammatory and oxidative signaling:** Experimental results include resistance to oxidative stress in tendon cells, changes in hippocampal inflammatory-signaling gene expression, and reduced inflammatory pathology in injured rat tissues. [6,13,19] These findings support possible tissue-specific mechanisms rather than a proven general anti-inflammatory.
- **Wound and skin repair:** Topical BPC-157 improved closure, re-epithelialization, granulation tissue, and collagen deposition in a rat alkali-burn model. Cell assays supported endothelial migration and vessel formation. Human wound-healing benefit remains plausible. [14]
- **Acute incisional pain:** A controlled rat study found reduced mechanical hypersensitivity at two hours, with the early effect absent at six hours, supporting a limited antinociceptive finding, not sustained analgesia or established treatment of human neuropathic pain. [15]
- **General recovery and nonspecific pain:** Broad claims about faster overall recovery or nonspecific pain relief remain speculative. The small knee series does not establish these general effects. [22]

Potential Applications

- **Tendon or ligament injury:** Repair benefits are plausible. [3,4,25]
- **Muscle injury:** Repair after direct muscle injury is a plausible translational application. [5,27,29]
- **Post-surgical tissue repair:** Benefit is plausible in soft-tissue and gastrointestinal settings. [3,12,28]
- **Gastrointestinal injury:** Human mucosal protection and repair are plausible. [12,13]
- **Peripheral nerve injury:** Rat sciatic-nerve experiments demonstrated axonal, electrophysiological, and walking recovery. Corresponding human nerve repair remains plausible. [16]
- **Neuropathic symptoms:** Symptom improvement after nerve injury is a possible translational hypothesis. [15,16]

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

Cautions

- **Active or recent cancer:** Experimental angiogenesis warrants caution. [8,21]
- **Pregnancy or breastfeeding:** Safety is not establish. [1,11]
- **Unstable blood pressure or vascular disease:** Nitric-oxide-dependent vasomotor effects create a plausible concern about altered vascular tone. [9]
- **Agents with overlapping repair effects:** Additive angiogenic, vasomotor, or remodeling effects remain speculative. [25]

Side Effects

- **Reported symptoms:** Reliable BPC-157-specific rates or causality have not been established for the headache, dizziness, appetite or digestive changes, fatigue, and lethargy sometimes attributed to community use.
- **Blood-pressure effects:** Experimental nitric-oxide signaling makes changes plausible. [9,24]

Biological Mechanism

Experimental studies indicate that BPC-157 influences several repair pathways. In endothelial cells and rat hind-limb ischemia, increased VEGFR2 expression and internalization accompanied VEGFR2–Akt–eNOS signaling and angiogenesis. This does not demonstrate direct binding to VEGFR2. [8] Separate experiments implicated Src–caveolin-1–eNOS signaling in nitric-oxide-dependent relaxation of isolated rat aorta. [9] These mechanisms make vascular repair effects biologically plausible.

In rat tendon-cell experiments, BPC-157 promoted migration, spreading, survival under oxidative stress, and explant outgrowth, with increased FAK and paxillin phosphorylation. It did not directly increase cultured tendon-fibroblast proliferation in that study. [6] Earlier animal studies showed improved collagen organization and biomechanical repair, but functional benefit was not statistically confirmed for BPC-157 in the newer independent experiment. [3,4,25]

In gastrointestinal animal models, experiments involving nitric-oxide manipulation support interaction with that system in fistula healing. [12] Protection despite NSAID exposure suggests that cytoprotection can occur under prostaglandin inhibition, rather than proving a defined direct prostaglandin target. [13] Improved anastomotic integrity, epithelial repair, and collagen formation were demonstrated in rats. [28] Human gastrointestinal repair remains a plausible extrapolation.

Animal central-nervous-system injury experiments reported reduced tissue damage and functional improvement. [17–19] Hippocampal gene-expression changes implicate stress-response, vascular, and inflammatory pathways, but do not establish which pathway causes protection or prove adequate human brain exposure. [19] The prolonged follow-up after a single spinal-injury treatment is not evidence of safety during prolonged dosing. [18]

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

Overall, BPC-157 has pleiotropic experimental repair effects. Cell migration, vascular signaling, and tissue-specific inflammatory responses offer plausible mechanisms; a single primary molecular target and a unified clinical repair effect remain unestablished. [1,6,8,9]

BPC-157 and Cancer Risk

BPC-157 promotes angiogenic signaling in experimental systems, making effects on tumor vascularization a plausible concern. [8] A 2004 conference abstract reported inhibition of melanoma-cell growth and VEGF signaling, but this remains a preliminary report rather than evidence of clinical antitumor activity. [21] Negative genotoxicity tests are reassuring for the tested mechanisms of DNA damage, but do not exclude promotion of an existing tumor. [11] Long-term carcinogenicity and recurrence risks remain insufficiently characterized. [1]

BPC-157 and Autoimmune Conditions

BPC-157 reduced adjuvant arthritis in rats, an observed experimental finding. [13] Its effects on inflammatory injury and gastrointestinal repair provide plausible mechanisms for benefit in selected autoimmune settings. [12,13,28] Efficacy in human rheumatoid arthritis, psoriasis, autoimmune gastritis, and other autoimmune disorders remains speculative.

Conclusions

BPC-157 has demonstrated repair-related effects in several animal and cellular systems. Corresponding human tissue repair is plausible, with inconsistent independent tendon results and limited clinical evidence constraining stronger conclusions. [3–9,22,23,25,27,28] Short human studies offer specific tolerability observations; they do not resolve liver, clotting, immunological, reproductive, or delayed risks from repeated exposure. [1,11,24] Human SC dosing, maintenance, and cycling remain speculative. [1,29]

References

- [1] US Food and Drug Administration. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 [free base] and BPC-157 acetate). Pharmacy Compounding Advisory Committee meeting; July 23-24, 2026. [Available online](#)
- [2] Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. *Curr Pharm Des.* 2011;17(16):1612-1632. [doi:10.2174/138161211796196954](https://doi.org/10.2174/138161211796196954)
- [3] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. *J Orthop Res.* 2003;21(6):976-983. [doi:10.1016/s0736-0266\(03\)00110-4](https://doi.org/10.1016/s0736-0266(03)00110-4)
- [4] Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. *J Orthop Res.* 2010;28(9):1155-1161. [doi:10.1002/jor.21107](https://doi.org/10.1002/jor.21107)

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

- [5] Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. *Med Sci Monit.* 2010;16(3):BR81-BR88. [PubMed](#)
- [6] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *J Appl Physiol* (1985). 2011;110(3):774-780. [doi:10.1152/japplphysiol.00945.2010](#)
- [7] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. *Cell Tissue Res.* 2019;377(2):153-159. [doi:10.1007/s00441-019-03016-8](#)
- [8] Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med (Berl).* 2017;95(3):323-333. [doi:10.1007/s00109-016-1488-y](#)
- [9] Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. *Sci Rep.* 2020;10(1):17078. [doi:10.1038/s41598-020-74022-y](#)
- [10] He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. *Front Pharmacol.* 2022;13:1026182. [doi:10.3389/fphar.2022.1026182](#)
- [11] Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. *Regul Toxicol Pharmacol.* 2020;114:104665. [doi:10.1016/j.yrtph.2020.104665](#)
- [12] Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. *J Pharmacol Sci.* 2008;108(1):7-17. [doi:10.1254/jphs.FP0072161](#)
- [13] Sikiric P, Seiwerth S, Grabarevic Z, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. *J Physiol Paris.* 1997;91(3-5):113-122. [doi:10.1016/S0928-4257\(97\)89474-0](#)
- [14] Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. *Drug Des Devel Ther.* 2015;9:2485-2499. [doi:10.2147/DDDT.S82030](#)
- [15] Jung YH, Kim H, Kim H, Kim E, Baik J, Kang H. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. *J Dent Anesth Pain Med.* 2022;22(2):97-105. [doi:10.17245/jdapm.2022.22.2.97](#)

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

- [16] Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. *Regul Pept.* 2010;160(1-3):33-41. [doi:10.1016/j.regpep.2009.11.005](https://doi.org/10.1016/j.regpep.2009.11.005)
- [17] Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. *Regul Pept.* 2010;160(1-3):26-32. [doi:10.1016/j.regpep.2009.11.012](https://doi.org/10.1016/j.regpep.2009.11.012)
- [18] Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. *J Orthop Surg Res.* 2019;14(1):199. [doi:10.1186/s13018-019-1242-6](https://doi.org/10.1186/s13018-019-1242-6)
- [19] Vukojević J, Vrdoljak B, Malekinušić D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. *Brain Behav.* 2020;10(8):e01726. [doi:10.1002/brb3.1726](https://doi.org/10.1002/brb3.1726)
- [20] Zenko Sever A, Sever M, Vidovic T, et al. Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. *Eur J Pharmacol.* 2019;847:130-142. [doi:10.1016/j.ejphar.2019.01.030](https://doi.org/10.1016/j.ejphar.2019.01.030)
- [21] Radeljak S, Seiwerth S, Sikiric P. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. *Melanoma Res.* 2004;14(4):A14-A15. [doi:10.1097/00008390-200408000-00050](https://doi.org/10.1097/00008390-200408000-00050) Conference abstract; original text not independently verified.
- [22] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. *Altern Ther Health Med.* 2021;27(4):8-13. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34812341/)
- [23] Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. *Altern Ther Health Med.* 2024;30(10):12-17. [PubMed](https://pubmed.ncbi.nlm.nih.gov/43812341/)
- [24] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. *Altern Ther Health Med.* 2025;31(5):20-24. [PubMed](https://pubmed.ncbi.nlm.nih.gov/45812341/)
- [25] Biçer O, Adanir O, Güleriyüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. *Jt Dis Relat Surg.* 2026;37(3):822-837. [doi:10.52312/jdrs.2026.2951](https://doi.org/10.52312/jdrs.2026.2951)
- [26] US Food and Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Published July 2005. [Available online](https://www.fda.gov/oc/ohrt/guidance.htm)
- [27] Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. *J Orthop Res.* 2006;24(5):1109-1117. [doi:10.1002/jor.20089](https://doi.org/10.1002/jor.20089)

BPC-157 Available for Research Use Only

Injury 100–500 mcg SC once or twice daily for 2–8 weeks

[28] Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. *Surg Today*. 2007;37(9):768-777. [doi:10.1007/s00595-006-3498-9](https://doi.org/10.1007/s00595-006-3498-9)

[29] Hudson Biotech. BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov identifier: NCT07437547. Accessed October 17, 2026. [Available online](#)